FDA Supplement Health Claim Actions Draw Congressional Criticism
This article was originally published in The Tan Sheet
FDA's recent actions regarding dietary supplement health claims are "cause for concern" and "sacrifice First Amendment rights for administrative convenience," Rep. Peter DeFazio (D-Ore.) states in a Jan. 12 letter to Commissioner Jane Henney, MD.
You may also be interested in...
FDA plans to hold a public meeting in the first quarter of 2000 to discuss possible ways to amend its general health claims regulations for dietary supplements, the agency announced in a Dec. 1 Federal Register notice.
Pending health claims petitions for dietary supplements containing vitamin E, saw palmetto, pysllium, and folic acid/vitamins B6 and B12 are based on "such a favorable risk/benefits ratio that the public should be given proper information concerning the potential benefits of these nutraceuticals," Harry Preuss, MD, Georgetown University Medical Center, maintained at a May 25 press conference on Capitol Hill.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC